Loading
An immunotoxin for hairy cell leukaemia that produced lasting remissions in relapsed patients but was withdrawn from sale in 2023 for commercial reasons.
Moxetumomab pasudotox is a recombinant immunotoxin: an anti-CD22 Fv fragment fused to a truncated Pseudomonas exotoxin A (PE38). After binding CD22 it is internalised and inactivates elongation factor 2 by ADP-ribosylation, shutting down protein synthesis in the leukaemic cell. It was approved in the US in 2018 for relapsed or refractory hairy cell leukaemia after at least two systemic therapies including a purine analogue. The pivotal study (Kreitman, Leukemia 2018) achieved a 41% complete remission rate, 30% of them durable, in multiply relapsed patients; capillary leak and haemolytic uraemic syndrome were the key toxicities. AstraZeneca withdrew it from the US market in 2023 because of low use, with compassionate supply continuing through the NIH. It remains an example of an effective rare-disease drug that failed commercially rather than clinically.
Recombinant anti-CD22 Fv fused to truncated Pseudomonas exotoxin PE38; internalised and inhibits protein synthesis via ADP-ribosylation of EF-2. Connects to CD22.
1.Moxetumomab pasudotox's antibody arm binds CD22 on the surface of the cancer cell.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 2018 | Relapsed/refractory hairy cell leukaemia after ≥2 systemic therapies including a purine analogue · Withdrawn from market 2023 |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Moxetumomab pasudotox" OR ABSTRACT:"Moxetumomab pasudotox" OR TITLE:"Lumoxiti" OR ABSTRACT:"Lumoxiti") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Moxetumomab pasudotox, not a curated reading list.
Shares CD22, AstraZeneca.
Shares CD22, Antibody-drug conjugate (ADC).
Shares CD22, Antibody-drug conjugate (ADC).
Shares CD22, Antibody-drug conjugate (ADC).
Shares CD22, Antibody-drug conjugate (ADC).